Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.

Clinical and experimental rheumatology - 1 Jan 2000

Anton Jordi, Calvo Inmaculada, Fernández-Martin Julián, Gamir Mari Luz, Merino Rosa, Jimenez-Treviño Santiago, Sevilla Belen, Cabades Francisco, Bou Rosa, Arostegui Juan I

Abstract excerpt

OBJECTIVES: Cryopyrin-associated periodic syndromes (CAPS) are dominantly-inherited autoinflammatory diseases. The uncontrolled IL-1β overproduction observed in these patients is the rational basis to treat them with anti-IL-1 drugs. The objective of this study was to evaluate the efficacy and safety of treatment with the long-lasting fully humanised anti-IL-1β monoclonal antibody canakinumab in a Spanish cohort...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cryopyrin-Associated Periodic Syndromes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Immunosuppressive Agents

Share to Interleukin-1beta

Share to NLR Family, Pyrin Domain-Containing 3 Protein

Share to Remission Induction

Source

Identifiers

PMID: 26243511

Genes

CAPS
NLRP3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of canakinumab in cryopyrin-associated periodic syndromes: results from a Spanish cohort.PMID 26243511Read ↗

Canakinumab for the treatment of cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.Semantic proximity Read ↗

Use of canakinumab in the cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.Semantic proximity Read ↗

Pharmacological treatment options for cryopyrin-associated periodic syndromes.Semantic proximity Read ↗

The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: background and therapeuticsSemantic proximity Read ↗

Guidelines for the management and treatment of periodic fever syndromes: Cryopyrin-associated periodic syndromes (cryopyrinopathies - CAPS).Semantic proximity Read ↗

Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory?Semantic proximity Read ↗

Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome.Semantic proximity Read ↗

Cryopyrin-associated periodic syndromes: diagnosis and management.Semantic proximity Read ↗

[CAPS: cryopyrin-associated periodic syndrome].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.